Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationEBIATLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - Other
Ratios

Barinthus Biotherapeutics (BRNS) Receivables - Net (2020 - 2023)

Barinthus Biotherapeutics' Receivables - Net history spans 4 years, with the latest figure at $172000.0 for Q1 2023.

  • For Q1 2023, Receivables - Net fell 99.05% year-over-year to $172000.0; the TTM value through Mar 2023 reached $172000.0, down 99.05%, while the annual FY2022 figure was $5.5 million, 27400.0% up from the prior year.
  • Receivables - Net reached $172000.0 in Q1 2023 per BRNS's latest filing, down from $5.5 million in the prior quarter.
  • In the past five years, Receivables - Net ranged from a high of $18.0 million in Q1 2022 to a low of $20000.0 in Q4 2021.
  • Average Receivables - Net over 4 years is $2.7 million, with a median of $172000.0 recorded in 2023.
  • Peak YoY movement for Receivables - Net: surged 27400.0% in 2022, then tumbled 99.05% in 2023.
  • A 4-year view of Receivables - Net shows it stood at $518000.0 in 2020, then plummeted by 96.14% to $20000.0 in 2021, then soared by 27400.0% to $5.5 million in 2022, then plummeted by 96.87% to $172000.0 in 2023.
  • Per Business Quant, the three most recent readings for BRNS's Receivables - Net are $172000.0 (Q1 2023), $5.5 million (Q4 2022), and $26000.0 (Q3 2022).